2026 · 2nd Quarter (Apr 1 - June 30)

ELI LILLY & COMPANY

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: ELI LILLY & COMPANY
Filing UUID: 86cca2da-2d31-4aa1-8ba2-d94d82341a80
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Drug importation, prescription drug safety, value and access.

TAX · Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

HCR · Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794).

Literal federal measure citations: HR6509, S3794

MMM · Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

BUD · Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

TRD · Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

DEF · Defense

Issues related to pharmaceutical manufacturing and development.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.